Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Laboratory models of breast and endometrial cancer to develop strategies for antiestrogen therapy.

O'Regan RM, England GM, Macgregor JI, Yao KA, Muenzner HD, Takei H, Jordan VC.

Breast Cancer. 1998;5(3):211-7. doi: 10.1007/BF02966699.

PMID:
18841334
2.

Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.

O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis VJ, Bilimoria MM, Piette M, Dragan YP, Pitot HC, Chatterton R, Jordan VC.

J Natl Cancer Inst. 1998 Oct 21;90(20):1552-8.

PMID:
9790548
3.

Basic guide to the mechanisms of antiestrogen action.

MacGregor JI, Jordan VC.

Pharmacol Rev. 1998 Jun;50(2):151-96. Review.

PMID:
9647865
4.

Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapy.

Jordan VC, MacGregor JI, Tonetti DA.

Clin Oncol (R Coll Radiol). 1997;9(6):390-4. Review. No abstract available.

PMID:
9448968
5.

Tamoxifen: from breast cancer therapy to the design of a postmenopausal prevention maintenance therapy.

Jordan VC, MacGregor JI, Tonetti DA.

Osteoporos Int. 1997;7 Suppl 1:S52-7. Review. No abstract available.

PMID:
9205647
6.

The PapG tip adhesin of P fimbriae protects Escherichia coli from neutrophil bactericidal activity.

Tewari R, Ikeda T, Malaviya R, MacGregor JI, Little JR, Hultgren SJ, Abraham SN.

Infect Immun. 1994 Dec;62(12):5296-304.

7.

Mast cell phagocytosis of FimH-expressing enterobacteria.

Malaviya R, Ross EA, MacGregor JI, Ikeda T, Little JR, Jakschik BA, Abraham SN.

J Immunol. 1994 Feb 15;152(4):1907-14.

PMID:
8120397
8.

Neutrophil activation by nascent FimH subunits of type 1 fimbriae purified from the periplasm of Escherichia coli.

Tewari R, MacGregor JI, Ikeda T, Little JR, Hultgren SJ, Abraham SN.

J Biol Chem. 1993 Feb 5;268(4):3009-15.

Supplemental Content

Loading ...
Support Center